Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Cancer ; 19(1): 1018, 2019 Oct 29.
Article in English | MEDLINE | ID: mdl-31664947

ABSTRACT

BACKGROUND: Neuroblastoma (NB) is a frequent pediatric tumor associated with poor prognosis. The disregulation of Bcl-2, an anti-apoptotic protein, is crucial for the tumoral development and chemoresistance. Autophagy is also implicated in tumor cell survival and chemoresistance. The aim of our study was to demonstrate therapeutic efficiency of GX 15-070, a pan-Bcl-2 family inhibitor, used alone and in combination with conventional drugs or with hydroxychloroquine (HCQ), an autophagy inhibitor. METHODS: Five neuroblastoma cell lines were tested for the cytotoxic activity of GX 15-070 alone or in combination with cisplatin, doxorubicin, HCQ or Z-VAD-FMK a broad-spectrum caspase inhibitor. Apoptosis and autophagy levels were studied by western-blot and FACS. Orthotopic injections were performed on NOD/LtSz-scid/IL-2Rgamma null mice that were treated with either GX 15-070 alone or in combination with HCQ. RESULTS: Synergistic cytotoxicity was observed for the drug combination in all of the 5 neuroblastoma cell lines tested, including MYCN amplified lines and in cancer stem cells. GX 15-070 significantly increased apoptosis and autophagy in neuroblastoma cells as evidenced by increased levels of the autophagy marker, LC3-II. Inhibition of autophagy by HCQ, further increased the cytotoxicity of this combinatorial treatment, suggesting that autophagy induced by these agent plays a cytoprotective role. In vivo, GX 15-070 combined with HCQ significantly decreased the growth of the tumor and the number of distant metastases. CONCLUSIONS: Based on the synergistic effect of HCQ and GX 15-070 observed in this study, the combination of these two drugs may be utilized as a new therapeutic approach for neuroblastoma.


Subject(s)
Adrenal Gland Neoplasms/metabolism , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Autophagy/drug effects , Drug Resistance, Neoplasm/drug effects , Neuroblastoma/metabolism , Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors , Pyrroles/pharmacology , Adrenal Gland Neoplasms/drug therapy , Adrenal Gland Neoplasms/pathology , Animals , Antineoplastic Agents/therapeutic use , Cell Line, Tumor , Cell Survival/drug effects , Drug Synergism , Female , Humans , Hydroxychloroquine/pharmacology , Hydroxychloroquine/therapeutic use , Indoles , Male , Mice , Mice, Inbred NOD , Mice, SCID , Neuroblastoma/drug therapy , Neuroblastoma/pathology , Pyrroles/therapeutic use , Tumor Burden/drug effects , Xenograft Model Antitumor Assays
2.
Pediatr Dev Pathol ; 21(4): 355-362, 2018.
Article in English | MEDLINE | ID: mdl-29067879

ABSTRACT

Neuroblastoma, a malignant neoplasm of the sympathetic nervous system, is one of the most aggressive pediatric cancers. Patients with stage IV high-risk neuroblastoma receive an intensive multimodal therapy ending with an immunotherapy based on a chimeric monoclonal antibody ch14.18. Although the use of ch14.18 monoclonal antibody has significantly increased the survival rate of high-risk neuroblastoma patients, about 33% of these patients still relapse and die from their disease. Ch14.18 targets the disialoganglioside, GD2, expressed on neuroblastic tumor (NT) cells. To better understand the causes of tumor relapse following ch14.18 immunotherapy, we have analyzed the expression of GD2 in 152 tumor samples from patients with NTs using immunohistochemical stainings. We observed GD2 expression in 146 of 152 samples (96%); however, the proportion of GD2-positive cells varied among samples. Interestingly, low percentage of GD2-positive cells before immunotherapy was associated with relapse in patients receiving ch14.18 immunotherapy. In addition, we demonstrated in vitro that the sensitivity of neuroblastoma cell lines to natural killer-mediated lysis was dependent on the proportion of GD2-positive cells, in the presence of ch14.18 antibody. In conclusion, our results indicate that the proportion of tumor cells expressing GD2 in NTs should be taken in consideration, as a prognostic marker, for high-risk neuroblastoma patients receiving anti-GD2 immunotherapy.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Biomarkers, Tumor/metabolism , Gangliosides/metabolism , Neuroblastoma/metabolism , Adolescent , Child , Child, Preschool , Female , Follow-Up Studies , Gangliosides/antagonists & inhibitors , Humans , Immunohistochemistry , Infant , Infant, Newborn , Male , Neoplasm Recurrence, Local/diagnosis , Neoplasm Recurrence, Local/etiology , Neuroblastoma/diagnosis , Neuroblastoma/drug therapy , Neuroblastoma/mortality , Prognosis , Treatment Outcome
3.
BMC Cancer ; 16(1): 891, 2016 11 15.
Article in English | MEDLINE | ID: mdl-27846885

ABSTRACT

BACKGROUND: Neuroblastoma (NB) is a frequent pediatric tumor characterized by a poor prognosis where a majority of tumors progress despite intensive multimodality treatments. Autophagy, a self-degradative process in cells, could be induced by chemotherapy and be associated with chemoresistance. The aim of this study was to determine whether: 1) autophagy is present in NB, 2) chemotherapy modified its levels, and 3) its inhibition decreased chemoresistance. METHODS: Immunohistochemical stainings were performed on samples from 184 NB patients in order to verify the expression of LC3B, a specific marker for autophagy, and Beclin 1, a positive regulator of autophagy. In addition, we performed an in vitro study with six NB cell lines and six drugs (vincristine, doxorubicin, cisplatin temozolomide, LY294002 and syrolimus). Inhibition of autophagy was performed using ATG5 knockdown cells or hydroxychloroquine (HCQ). Cell survival was measured using the MTT cell proliferation assay. Autophagy was detected by monodansylcadaverine, confocal microscopy and Western blot. In vivo study with tumor xenografts in NSG mice was performed. RESULTS: Our results have indicated that autophagy was present at low levels in NB and was not a prognostic factor, while Beclin 1 was highly expressed in children with poor NB prognosis. However, autophagy levels increased after chemotherapy in vitro and in vivo. Tumor progression was significantly decreased in mice treated with a combination of HCQ and vincristine. CONCLUSIONS: Taken together, autophagy is present in NB, induced by chemotherapy and associated with chemoresistance, which is significantly reduced by its inhibition. Therefore, targeting autophagy represents a very attractive approach to develop new therapeutic strategies in NB.


Subject(s)
Antineoplastic Agents/pharmacology , Autophagy/drug effects , Autophagy/genetics , Drug Resistance, Neoplasm/genetics , Neuroblastoma/genetics , Neuroblastoma/metabolism , Animals , Antineoplastic Agents/therapeutic use , Autophagy-Related Protein 5/genetics , Autophagy-Related Protein 5/metabolism , Biomarkers , Cell Line, Tumor , Cell Proliferation , Child , Child, Preschool , Disease Models, Animal , Disease Progression , Follow-Up Studies , Gene Knockout Techniques , Humans , Immunohistochemistry , Infant , Infant, Newborn , Mice , Mice, Knockout , Neoplasm Staging , Neuroblastoma/diagnosis , Neuroblastoma/drug therapy , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism
4.
J Clin Pathol ; 68(6): 434-40, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25770162

ABSTRACT

AIMS: CD133 expression in cancer is frequently associated with poor outcome. Thyroid carcinomas are rare in childhood and adolescence and are associated with a higher risk of recurrence and more metastases than the adult tumours. The aim of the study was to assess whether the expression of CD133 in thyroid carcinomas of children, adolescents and young adults was correlated with clinical prognostic factors. METHODS: Tissue microarrays were constructed with 235 tumours coming from 208 young adults with a median age of 28 years and 27 children with a median age of 13 years. An immunohistochemical study was performed with anti-CD133 antibody. CD133 expression was evaluated, using a semiquantitative score based on the percentage of positive cells. The mutation status of tumours was evaluated by reverse transcriptase PCR. Three cell lines were used to confirm CD133 expression by western blot. RESULTS: CD133 expression was found in 43% of adult and 37% of child tumours and was confirmed by western blot in cell lines. In young adults, the expression of CD133 was significantly more frequent in patients with tumours >3 cm (p=0.04) and in patients with lymph node metastases (p=0.02). The expression of CD133 was more frequent in patients in whom the tumour presented a BRAF mutation (p=0.03). CONCLUSIONS: CD133 expression is correlated with tumour size, lymph nodes metastases and BRAF mutations in young adults. The presence of these cancer stem cells could offer new therapeutic alternatives for aggressive thyroid cancers.


Subject(s)
Antigens, CD/metabolism , Biomarkers, Tumor/metabolism , Glycoproteins/metabolism , Peptides/metabolism , Thyroid Neoplasms/diagnosis , AC133 Antigen , Adolescent , Adult , Carcinoma/diagnosis , Carcinoma/genetics , Carcinoma, Papillary , Cell Line, Tumor , Child , Female , Humans , Lymphatic Metastasis , Male , Prognosis , Proto-Oncogene Proteins B-raf/genetics , Thyroid Cancer, Papillary , Thyroid Gland/metabolism , Thyroid Neoplasms/genetics , Young Adult
5.
Histopathology ; 64(5): 731-40, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24433523

ABSTRACT

AIMS: Lipoblastoma is a benign neoplasm of embryonic white fat tissue that results from the proliferation of primitive adipocytes, in which histological features can be ambiguous. In order to discriminate between lipoblastoma and other lipogenic and lipomatous tumours, we studied chromosomal alterations and protein expression in two cases of lipoblastoma in infants. METHODS AND RESULTS: Standard cytogenetic analysis, fluorescence in-situ hybridization, array comparative genomic hybridization and Western blotting allowed us to demonstrate the presence of chromosome abnormalities involving the 8q11-13 region containing the pleomorphic adenoma gene 1 (PLAG1), which are classically reported in lipoblastoma, and aberrant expression of PLAG1. CONCLUSIONS: This report illustrates two different tumorigenic pathways implicating PLAG1 in lipoblastoma: amplification through multiple copies of a small marker chromosome derived from chromosome 8, and a paracentric inversion of the long arm of chromosome 8. Both these anomalies induced aberrant expression of PLAG1, emphasizing the role of PLAG1 in tumorigenesis. The aberrant expression of PLAG1 protein has been hypothesized, but this is the first report to demonstrate its occurrence in lipoblastoma.


Subject(s)
Chromosome Aberrations , Chromosomes, Human, Pair 8/genetics , DNA-Binding Proteins/genetics , Lipoblastoma/diagnosis , Lipoblastoma/genetics , Soft Tissue Neoplasms/diagnosis , Soft Tissue Neoplasms/genetics , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Child, Preschool , Chromosome Inversion , Comparative Genomic Hybridization , Cytogenetic Analysis , DNA-Binding Proteins/metabolism , Female , Gene Amplification , Gene Expression , Humans , In Situ Hybridization, Fluorescence , Infant , Lipoblastoma/pathology , Male , Soft Tissue Neoplasms/pathology
6.
Genes Chromosomes Cancer ; 51(8): 792-804, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22514116

ABSTRACT

Neuroblastoma (NB) is the most common and lethal extracranial solid tumor of childhood. Despite aggressive therapy, more than half of the children with advanced NB will die of uncontrolled metastatic disease. After chemotherapy, tumor-initiating cells (TICs) could persist, cause relapses and metastasis. The aim of this study is to demonstrate the tumor-initiating properties of CD133high NB cells and to identify new specific genetic abnormalities. Isolation of the CD133high cell population from NB cell lines was followed by neurosphere formation, soft agar assays, and orthotopic injections in NOD/SCID/IL2Rγc-null mice. A differential genotyping analysis was performed with Affymetrix SNP 6.0 arrays on CD133low and CD133high populations and the frequency of the abnormalities of 36 NB tumors was determined. Our results show that CD133high NB cells possess tumor-initiating properties, as CD133high cells formed significantly more neurospheres and produced significantly more colonies in soft agar than CD133low. Injection of 500 CD133high cells was sufficient to generate primary tumors and frequent metastases in mice. Differential genotyping analysis demonstrated two common regions with gains (16p13.3 and 19p13.3) including the gene EFNA2 in the CD133high population, and two with loss of heterozygosity (16q12.1 and 21q21.3) in the CD133low population. The gain of EFNA2 correlated with increased expression of the corresponding protein. These abnormalities were found in NB samples and some were significantly correlated with CD133 expression. Our results show that CD133high NB cells have TICs properties and present different genotyping characteristics compared to CD133low cells. Our findings reveal insights into new therapeutic targets in NB TICs.


Subject(s)
Antigens, CD/genetics , Glycoproteins/genetics , Neuroblastoma/genetics , Peptides/genetics , AC133 Antigen , Adrenal Gland Neoplasms , Animals , Antigens, CD/biosynthesis , Antigens, CD/metabolism , Cell Line, Tumor , Cell Separation , Chi-Square Distribution , Chromosome Aberrations , Female , Genotype , Glycoproteins/biosynthesis , Glycoproteins/metabolism , Humans , Male , Mice , Mice, Inbred NOD , Mice, SCID , Mutagenesis, Insertional , Neoplasm Transplantation , Neuroblastoma/metabolism , Peptides/metabolism , Polymorphism, Single Nucleotide
SELECTION OF CITATIONS
SEARCH DETAIL
...